My research focuses on the development and optimization of a novel hybrid biological-biomaterial vector for use in cancer immunotherapy. The hybrid vector (HV) uses natural bacterial structures and synthetic biomaterials to target dendritic cells (DC) to result in optimal maturation and antigen delivery, which is a critical step in the activation of cytotoxic T cells. Through a variety of immunological methods, I will examine the ability of the vector to improve DC uptake, DC maturation, antigen delivery, and antigen-specific T cell activation and proliferation, both in an in vitro and in vivo context.

Jason Muhitch, PhD & Blaine Pfeifer, PhD